A Study to Test Whether Different Doses of BI 456906 Help People With Overweight or Obesity to Lose Weight
NCT04667377 on ClinicalTrials.gov · last registry update 2023-11-02
An unusually large phase 2: 387 participants, more than double the 110 typical for the stage. The sponsor logged completion for 15 September 2022. Primary outcome, as filed: Percentage Change in Body Weight From Baseline to Week 46. survodutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended.
- Status
- COMPLETED
- Phase
- P2
- Drug
- survodutide
- Sponsor
- Boehringer Ingelheim
- Sponsor type
- Industry
- Enrollment
- 387
- Started
- 2021-03-08
- Primary completion
- 2022-09-15 actual
Observed history
No changes recorded since monitoring began on 2026-08-21. This record has held steady. If a reporting date moves, a status changes or enrollment is resized, it will appear here with the previous value alongside the new one.
Primary outcome
Percentage Change in Body Weight From Baseline to Week 46
Conditions studied
Obesity
Every field above is taken directly from the registry record. See all detected changes across the class, or the survodutide page for this molecule’s full trial and approval history.